How Aspen Was Built: Saad, Attridge and the 1999 Acquisition

A start-up and an acquired industrial history

Aspen’s modern operating story began in 1997. Stephen Saad and Gus Attridge were two of four founding members, not the entire founding team. Aspen Healthcare began trading that year. ^[3]

The group’s history places the trading base in a converted house in Greyville, Durban. That small beginning differs sharply from the factories acquired later. A founder story should explain both stages without treating every acquired asset as something the founders created. ^[1]

Three early milestones provide a useful guide: trading began in 1997, a reverse listing followed in 1998, and a major acquisition followed in 1999. Each date answers a different question about how the business developed. ^[2]

The 1998 listing was not the 1997 trading start

Aspen’s 2013 integrated report records a reverse listing into Medhold Limited in 1998. This describes the route to a stock-market listing. It does not mean the founders first began trading in 1998. ^[3]

A reverse listing uses an existing listed company as the vehicle for a business entering the market. The important point here is the sequence. The operating venture existed before that listing transaction, while the listed structure provided a different corporate milestone. ^[2]

Medhold appears here as the predecessor listing vehicle in Aspen’s corporate history. It is not presented as another newly founded pharmaceutical group. The existing Aspen record carries that relationship so readers do not encounter a duplicate modern company entry. ^[2]

The R2.4 billion transaction changed the scale

In 1999, Aspen acquired the pharmaceutical business of South African Druggists for R2.4 billion. Its corporate timeline describes a hostile takeover. The acquired business was an established pharmaceutical operation, not a new trading name created for the Greyville start-up. ^[3]

The 2008 annual report gives 1 March 1999 as the acquisition date for the South African Druggists businesses. That precise date complements the year used in later corporate timelines. It also separates the acquisition from the previous year’s reverse listing. ^[2]

The transaction amount describes the acquisition, not either founder’s personal investment or ownership percentage. Nor does a business acquisition establish that the founders personally owned every acquired factory. Corporate assets and personal shareholdings are different parts of the story. ^[3]

What the acquired factories contributed

Aspen’s June 2014 investor presentation identifies manufacturing facilities acquired from South African Druggists in March 1999. They were in Port Elizabeth, East London and Johannesburg. The presentation describes the Port Elizabeth heritage facility as an established operation on its existing site. ^[4]

The acquisition therefore brought an industrial base as well as a larger business. It would be misleading to describe the inherited facilities as entirely new factories built in 1997. The founders’ contribution included acquiring and developing capacity that already existed. ^[4]

Later investment formed another stage. A joint Aspen and government statement records continued spending on the Port Elizabeth operations after the 1999 purchase. It describes manufacturing across oral solid, liquid, sterile and specialised high-potency products. ^[5]

The same statement links international market access to regulatory approvals and manufacturing capability. The business lesson is broader than buying a factory. Expansion also required investment in production systems, technical skills and the standards needed to supply other markets. ^[5]

These are historical descriptions of the manufacturing platform. They are not current capacity figures or a claim that every facility and approval remains unchanged. A dated site presentation should not become an undated description of today’s operations. ^[4]

The people and businesses in this history

Attridge’s finance role and later advisory work

Aspen’s 2021 executive committee page describes Attridge as Deputy Group Chief Executive and finance director. His responsibilities included the group’s financial wellbeing and pursuing corporate opportunities. That record places financial management alongside the acquisition story, rather than treating growth as one person’s work. ^[6]

The 2022 integrated report records his retirement from those executive and board roles on 31 December 2021. It also says he remained employed as Group Chief Advisor and continued on the executive committee in that capacity. Retirement from those posts did not mean departure from Aspen. ^[7]

As checked on 15 October 2026, Aspen’s leadership page still lists Attridge as Group Chief Advisor. The former deputy chief executive title should therefore carry its historical context. An old annual report remains evidence of an earlier role, not proof of a current appointment. ^[1]

Founding, management and ownership are not interchangeable

Aspen’s FY2026 results identify Saad as Group Chief Executive. The release reports on the year ended 30 June 2026. It supplies a dated check on his management role, rather than an undated assumption based on his founding status. ^[8]

A chief executive manages the group, while shareholders hold equity and exercise the voting rights attached to their shares. Those rights do not follow automatically from a job title. This history does not infer personal voting control from either man’s founding contribution. ^[7]

The early Aspen story is consequently more precise than a simple start-up success tale. It combines a trading venture, an existing listing vehicle and an acquired pharmaceutical platform. Keeping those elements separate makes the founders’ work easier to understand without erasing the business they bought. ^[3]

Frequently asked questions

Who founded Aspen? Stephen Saad and Gus Attridge were two of four founding members of Aspen Healthcare, which began trading in 1997. ^[1]

Did Aspen list when it began trading? No. Trading began in 1997, and the reverse listing into Medhold followed in 1998. ^[2]

What did Aspen buy in 1999? The pharmaceutical business of South African Druggists, for R2.4 billion. ^[3]

Is Gus Attridge still deputy chief executive? No. He retired from that role at the end of 2021 and remained employed as Group Chief Advisor. ^[7]